Ex­clu­sive: Lil­ly-backed Or­so­Bio rais­es $67M for slate of obe­si­ty drugs as com­bi­na­tions take root

Cal­i­for­nia biotech start­up Or­so­Bio is bet­ting the fu­ture of obe­si­ty drugs lies in com­bi­na­tion ap­proach­es.

To get there, Or­so­Bio told End­points News that it raised …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER